Genzyme is committed to providing a high level of support to healthcare professionals. Renvela® (sevelamer carbonate) provides professionals with an important new treatment option for management of phosphorus without the concerns of calcium or metal accumulation. Renvela offers all the advantages of Renagel® (sevelamer hydrochloride) with the added benefit of a carbonate buffer. Sevelamer has been studied extensively with more than 150 publications and has been used for 9 years in more than 750,000 patients1. Renvela is manufactured by Genzyme, a leader in providing treatments for renal patients with mineral and bone disorders.
1. Data on file, Genzyme Corp.
Genzyme Renvela
Important Treatment Considerations
Renvela® (sevelamer carbonate) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis
Renvela is contraindicated in patients with bowel obstruction
Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation, or major GI tract surgery
Uncommon cases of bowel obstruction and perforation have been reported
Serum bicarbonate and chloride levels should be monitored
Vitamins D, E, K (coagulation parameters), and folic acid levels should be monitored
The most frequently occurring adverse reactions in a short-term study with sevelamer carbonate tablets were nausea and vomiting
In a short-term study of sevelamer carbonate powder dosed three times daily, adverse events were similar to those reported for sevelamer carbonate tablets
In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation
Cases of fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation have been reported
Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renvela
Patients should be informed to take Renvela with meals and to adhere to their prescribed diets.
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis
Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction
Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery
Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation
Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction
Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel
Patients should be informed to take Renagel with meals and to adhere to their prescribed diets
Genzyme Corporate
